ContextCastration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited.
What explains the poor prognosis of metastatic castration-resistant prostate cancer (CRPC)?The paper reveals that resistance to conventional hormone therapies is inevitable in high-risk metastatic CRPC, leading to a median overall survival improvement of only 2.4 months over mitoxantrone chemotherapy when treated with docetaxel.How do androgen receptor (AR) amplifications contribute to CRPC progression?Increased AR expression in CRPC has been demonstrated to shift treatment responses; for instance, bicalutamide may act as an agonist rather than an antagonist at high levels, as seen in numerous human tumor samples.What recent insights have emerged regarding the immunotherapeutic approaches for prostate cancer?Research shows that sipuleucel-T significantly improved overall survival by 4.1 months in asymptomatic CRPC patients compared to placebo, indicating a clinically significant immune-mediated antitumor effect.
The androgen receptor (AR) signaling axis plays a critical role in the development, function and homeostasis of the prostate. The classical action of AR is to regulate gene transcriptional processes via AR nuclear translocation, binding to…
There are >100 point mutations that appear in AR, and the majority of them present in the NTD or LBD region (4,23). In recent years, there are a number of studies regarding AR mutations including T878A, H875Y/T, W742C, L702H and F877L (24–26…